Vismodegib for the treatment of basal cell skin cancer

American Journal of Health-System Pharmacy

Volumn 70, Issue 12, 2013, Pages 1033-1038

  Poggi, Laura ^a   Kolesar, Jil M ^a,b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; POTASSIUM; SONIC HEDGEHOG PROTEIN; VISMODEGIB; ANILIDE; ANTINEOPLASTIC AGENT; PYRIDINE DERIVATIVE;

ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; ANOREXIA; BACKACHE; BASAL CELL CARCINOMA; CANCER CHEMOTHERAPY; DEHYDRATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG SOLUBILITY; DYSGEUSIA; FATIGUE; HAIR LOSS; HEART ATRIUM FIBRILLATION; HUMAN; HYPOCALCEMIA; KERATITIS; LYMPHOCYTOPENIA; MUSCLE CRAMP; MUSCLE SPASM; PNEUMONIA; POTASSIUM BLOOD LEVEL; QT PROLONGATION; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; TASTE DISORDER; UNDERWEIGHT; URINARY TRACT INFECTION; WEIGHT REDUCTION; ECONOMICS; ORAL DRUG ADMINISTRATION; PATHOLOGY; SALVAGE THERAPY; SKIN TUMOR;

ADMINISTRATION, ORAL; ANILIDES; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS, BASAL CELL; PYRIDINES; SALVAGE THERAPY; SKIN NEOPLASMS;

EID: 84886439949     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp120311     Document Type: Review

References (20)

1. American Cancer Society. What are the key statistics about basal and squamous cell skin cancers? www.cancer.org/cancer/skincancer-basalandsquamouscell/detailedguide/skin-cancer-basal-and-squamous-cell-key-statistics (accessed 2012 Jul 18).
2. National Comprehensive Cancer Network. NCCN guidelines version 2.2012 basal cell skin cancers. www.nccn.org (accessed 2012 Apr 22).
3. Housman TS, Feldman SR, Williford PM et al. Skin cancer is among the most costly of all cancers to treat for the Medicare population. J Am Acad Dermatol. 2003; 48:425-9.
4. Bath-Hextall FJ, Perkins W, Bong J et al. Interventions for basal cell carcinoma of the skin. Cochrane Database Syst Rev. 2007; 1:CD003412.
5. Roozeboom MH, Arits AH, Nelemans PJ et al. Overall treatment success after treatment of primary superficial basal cell carcinoma: a systematic review and meta-analysis of randomized and non-randomized trials. Br J Dermatol. 2012; 167:733-56.
6. Robarge KD, Brunton SA, Castanedo GM et al. GDC-0449 - a potent inhibitor of the hedgehog pathway. Bioorg Med Chem Lett. 2009; 19:5576-81.
7. Tang JY. Elucidating the role of molecular signaling pathways in the tumorigenesis of basal cell carcinoma. Semin Cutan Med Surg. 2011; 30(suppl):S6-9.
8. Von Hoff DD, LoRusso PM, Rudin CM et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med. 2009; 361:1164-72.
9. Graham RA, Lum BL, Cheeti S et al. Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein binding. Clin Cancer Res. 2011; 17:2512-20.
10. Graham R, Hop C, Borin M et al. Single- and multiple-dose intravenous and oral pharmacokinetics of the hedgehog pathway inhibitor vismodegib in healthy female subjects. Br J Clin Pharmacol. 2012; 74:788-96.
11. Graham RA, Lum BL, Morrison G et al. A single dose mass balance study of the hedgehog pathway inhibitor vismodegib (GDC-0449) in humans using accelerator mass spectrometry. Drug Metab Dispos. 2011; 39:1460-7.
12. Erivedge (vismodegib) package insert. South San Francisco, CA: Genentech USA; 2012.
13. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45:228-47.
14. Sekulic A, Migden MR, Oro AE et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012; 366:2171-9.
15. Bree AF, Shah MR, for the BCNS Colloquium Group. Consensus statement from the first international colloquium on basal cell nevus syndrome (BCNS). Am J Med Genet A. 2011; 155A:2091-7.
16. Tang JY, Mackay-Wiggan JM, Aszterbaum M et al. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med. 2012; 366:2180-8.
17. The Pharma Letter. Faster-than-expected FDA approval of Roche's vismodegib. www.thepharmaletter.com/file/110669/faster-than-expected-fda-approval-of-roches-vismodegib.html (accessed 2012 May 8).
18. Narayanan K, Hadid OH, Barnes EA. Mohs micrographic surgery versus surgical excision for periocular basal cell carcinoma. Cochrane Database Syst Rev. 2012; 2:CD007041.
19. Jefford M, Kiffer JD, Somers G et al. Metastatic basal cell carcinoma: rapid symptomatic response to cisplatin and paclitaxel. ANZ J Surg. 2004; 74:704-5.
20. McMillan R, Matsui W. Molecular pathways: the hedgehog signaling pathway in cancer. Clin Cancer Res. 2012; 18:4883-8.